SAN ANTONIO, January 25, 2022 /PRNewswire/ — Based on its recent analysis of the global artificial intelligence (AI) drug discovery industry, Frost & Sullivan honors Insilico Medicine with the Entrepreneurial Company of the Year Award 2022 in the global AI-based drug discovery industry.
Pharma.AI, Insilico’s end-to-end AI-based drug discovery and development platform, addresses challenges in chemistry, biology and digital medicine. The combined expertise of AI and drug discovery enables the identification of new targets, the generation of new molecules that do not exist in the chemical space and the prediction of clinical trial results. AI solutions and the verified automated AI platform are streamlining research and development (R&D) efforts, reshaping therapeutic discovery, and advancing precision medicine. Additionally, these solutions accelerate the research workflow, leading to rapid and cost-effective discovery and development.
According to Supriya Lala Kunduindustry analyst at Frost & Sullivan, “Insilico’s AI platforms integrate GANs, reinforcement learning (RL), and transformative neural networks to automate multi-targeting, polypharmacogy and holistic disease assessment. The company is working on AI-powered robotics to create driverless drug discovery as it moves toward advanced technologies and 100% automation.”
PandaOmics is one of Pharma.AI’s AI engines that integrates proteomics, transcriptomics and other types of data with advanced AI algorithms. PandaOmics supports the identification of target diseases and supports the search and identification of targets for different diseases. The AI-powered platform delivers complex algorithms that recommend relevant new drug target hypotheses in days rather than months, dramatically reducing drug discovery times.
Insilico Medicine also uses several algorithms that quickly evaluate targets for possible binding sites to meet the challenge of transitioning from target to small molecules with desired properties. Chemistry42, a small molecule generation engine from the Pharma.AI platform with 30 algorithms, identifies the right pockets and designs in days a range of molecules that do not exist in the chemical space. Additionally, the engine helps filter billions of generated molecules to identify molecules that are easy to synthesize and inexpensive to develop with the highest potential for success. Chemistry42MT a hardware-independent and scalable cloud and on-premises platform that can be licensed and tested by customers, delivers actionable new drug-like molecules in days.
“Insilico relies on its proprietary AI-based platforms to effectively address the challenges of identifying precise targets, developing novel molecular structures with desired parameters, and predicting clinical trial outcomes. His deep technical expertise facilitates the accelerated and cost-effective design of new therapeutic compounds and innovative drugs. discovery for cancer, fibrosis, infectious diseases and diseases related to aging. For example, in 2021, Insilico launched the first-in-human study of a potentially first-in-class drug candidate with a novel target for fibrosis. the company completed the entire discovery process from target discovery to preclinical candidate nomination in 18 months with a budget of $2.6 million. Additionally, Insilico named two preclinical candidates with novel molecular structure for chronic kidney disease anemia and inflammatory bowel disease within 12 months using its AI engine. Milestones like this completely validate Insilico’s AI platform as robust and efficient,” Kundu explained.
In addition to the two engines mentioned above which have already been released as software, InClinicoMT , another AI-powered engine in development by Insilico that could provide prediction of clinical trial outcomes also has exciting prospects. With Strong Overall Performance, Growing Partnerships, Focus on Innovation and Expertise in End-to-End Drug Discovery and Development, Insilico Medicine Wins Entrepreneurial Company of the Year Award 2022 by Frost & Sullivan in the Global AI-Based Drug Discovery Industry.
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in designing and implementing a strong growth strategy. The recipient has demonstrated strength in product and technology innovation, leadership in customer value, and speed in responding to market needs. The award examines emerging market participants in the industry and recognizes their best practices that are positioned for excellence in future growth.
The Frost & Sullivan Best Practice Awards recognize companies in various regional and global markets for outstanding achievement and superior performance in leadership, technology innovation, customer service and strategic product development. Industry analysts benchmark market players and measure performance through in-depth interviews, analysis, and in-depth secondary research to identify industry best practices.
About Frost & Sullivan
For six decades, Frost & Sullivan has been recognized worldwide for its role in helping investors, business leaders and governments navigate economic change and identify disruptive technologies, mega trends, new models commercial and corporate action, resulting in a continuous stream of growth opportunities to ensure future success. Contact us: start the discussion.
Kala Mani. S
Telephone: +603-2023 2037
E-mail: [email protected]
About Insilico Medicine
Insilico Medicine, an end-to-end AI-based drug discovery and development company, connects clinical trial biology, chemistry and analytics using next-generation AI systems. Insilico Medicine has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover new targets and design new molecular structures with desired properties. Insilico Medicine offers breakthrough solutions to discover and develop innovative drugs against cancer, fibrosis, immunity, central nervous system (CNS) diseases and age-related diseases. For more information, visit www.insilico.com.
SOURCE Frost & Sullivan